Natera Inc
NASDAQ:NTRA

Watchlist Manager
Natera Inc Logo
Natera Inc
NASDAQ:NTRA
Watchlist
Price: 168.32 USD 2.39% Market Closed
Market Cap: 20.8B USD
Have any thoughts about
Natera Inc?
Write Note

Natera Inc
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Natera Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Natera Inc
NASDAQ:NTRA
Change in Working Capital
-$59.6m
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
-36%
Abbvie Inc
NYSE:ABBV
Change in Working Capital
-$1.9B
CAGR 3-Years
-19%
CAGR 5-Years
-7%
CAGR 10-Years
-20%
Gilead Sciences Inc
NASDAQ:GILD
Change in Working Capital
$7.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Change in Working Capital
-$612m
CAGR 3-Years
30%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Change in Working Capital
-$793.5m
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Change in Working Capital
-$593.3m
CAGR 3-Years
28%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

Natera Inc
Glance View

Market Cap
20.9B USD
Industry
Biotechnology

Natera Inc. is a leading genomics company that specializes in genetic testing and precision medicine, aiming to revolutionize healthcare through advanced DNA analysis. Founded in 2004 and headquartered in Austin, Texas, Natera focuses on reproductive health, oncology, and organ transplant management, providing invaluable insights that help doctors make informed decisions for their patients. Its flagship products include non-invasive prenatal testing (NIPT), which has gained significant traction for its ability to assess fetal health with remarkable accuracy, along with tests for hereditary cancer risk and monitoring treatment response in cancer patients. By harnessing the power of next-generation sequencing and machine learning, Natera is positioned to disrupt traditional medical practices and improve patient outcomes. Investors looking at Natera will find a company poised for growth amid increasing demand for genetic testing and personalized medicine. The company benefits from a robust pipeline and an expanding customer base, bolstered by strategic collaborations with healthcare providers and insurance companies. As awareness of genetic testing continues to rise, Natera's innovative solutions could capture substantial market share, particularly in oncology, where early detection can dramatically impact treatment efficacy and survival rates. With strong financial backing, a commitment to research and development, and a vision to elevate the standard of care through data-driven insights, Natera represents a compelling opportunity for those seeking to invest in the future of healthcare.

NTRA Intrinsic Value
56.49 USD
Overvaluation 66%
Intrinsic Value
Price

See Also

What is Natera Inc's Change in Working Capital?
Change in Working Capital
-59.6m USD

Based on the financial report for Sep 30, 2024, Natera Inc's Change in Working Capital amounts to -59.6m USD.

What is Natera Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
-36%

Over the last year, the Change in Working Capital growth was -4 011%. The average annual Change in Working Capital growth rates for Natera Inc have been 6% over the past three years , and -36% over the past ten years .

Back to Top